Reporting 2024
Download our latest reports
Annual Report 2024
Half-Year Report 2024
Annual report 2024
Siegfried reports continued profitable growth fueled by strong underlying business
0.0
Increase: +1.8%
0.0
Increase: +4.5%
0.0
Increase: +4.7%
0.0
Increase: +24.0%
The year 2024 in review
July: CEO transition
Marcel Imwinkelried appointed as new CEO.
July: Grafton acquisition
Siegfried acquires an early-phase CDMO in Wisconsin (US) to strengthen its drug substances service offering
August: Lab opening in Minden
Siegfried opens new quality control lab in Minden to improve operational efficiency and ready the site for completion of new production plant
October: Strategy EVOLVE+ announced
Siegfried holds its first Capital Markets Day at its site in Barberà del Vallès, and announces strategy EVOLVE+
November: Lab opening for Siegfried DINAMIQS
Siegfried DINAMIQS opens new lab in Zurich, strengthening offering in the biologics space
November: R&D Center opening in Evionnaz
Siegfried opens new global R&D Center for Drug Substances in Evionnaz
November: SBTi submission
Siegfried submitted near term and net zero CO2 emission reduction targets to SBTi for validation
December: Dow Jones Best-In-Class Europe Index
Siegfried confirmed in the Dow Jones Best-In-Class Europe Index (formerly Dow Jones Sustainability Index Europe) for the fourth consecutive year.